One of the most potent combinational therapy strategies in HCC seems to be an immune checkpoint inhibitor combined with a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab or IBI305 (a biosimilar). Here, VEGFA is linked to hepatocellular carcinoma.